Lucienne Chatenoud

Lucienne Chatenoud's AcademicInfluence.com Rankings

Lucienne Chatenoud

Philosophy

#6804

World Rank

#9907

Historical Rank

Logic

#3910

World Rank

#5138

Historical Rank

philosophy Degrees

Lucienne Chatenoud

Biology

#9244

World Rank

#12427

Historical Rank

Immunology

#550

World Rank

#568

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Why Is Lucienne Chatenoud Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Lucienne Chatenoud's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. (2005) (909)
Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. (1994) (655)
TGF-β-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes (2003) (649)
Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition) (2019) (627)
CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. (1997) (408)
Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. (2006) (400)
IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells (2010) (391)
CD3-specific antibodies: a portal to the treatment of autoimmunity (2007) (363)
Suppressor T cells – they’re back and critical for regulation of autoimmunity! (2001) (325)
CD3-specific antibody-induced active tolerance: from bench to bedside (2003) (303)
Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass (2010) (302)
IN VIVO CELL ACTIVATION FOLLOWING OKT3 ADMINISTRATION: SYSTEMIC CYTOKINE RELEASE AND MODULATION BY CORTICOSTEROIDS (1990) (289)
Tolerance to islet autoantigens in type 1 diabetes. (2001) (263)
Cytokine‐related syndrome following injection of anti‐CD3 monoclonal antibody: Further evidence for transient in vivo T cell activation (1990) (260)
Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells. (2005) (256)
Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma [corrected]. (1989) (252)
Convalescent plasma therapy for B-cell–depleted patients with protracted COVID-19 (2020) (225)
Cutting Edge: Immunological Consequences and Trafficking of Human Regulatory Macrophages Administered to Renal Transplant Recipients (2011) (222)
Adaptive TGF-β-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment (2007) (213)
The generation of a humanized, non‐mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties (1993) (210)
DEFICIT OF SUPPRESSOR T CELLS IN ACTIVE MULTIPLE SCLEROSIS (1980) (206)
Human in vivo antigenic modulation induced by the anti‐T cell OKT3 monoclonal antibody (1982) (196)
METABOLIC AND IMMUNOLOGICAL EFFECTS OF CYCLOSPORIN IN RECENTLY DIAGNOSED TYPE 1 DIABETES MELLITUS (1985) (192)
Antibiotics in Early Life Alter the Gut Microbiome and Increase Disease Incidence in a Spontaneous Mouse Model of Autoimmune Insulin-Dependent Diabetes (2015) (185)
The mechanisms of inhibition of human IL 2 production. II. PGE2 induction of suppressor T lymphocytes. (1984) (179)
Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3. (1986) (179)
Aberrant T cell-mediated immunity in untreated schizophrenic patients: deficient interleukin-2 production. (1989) (161)
Treatment with Nonmitogenic Anti-CD3 Monoclonal Antibody Induces CD4+ T Cell Unresponsiveness and Functional Reversal of Established Experimental Autoimmune Encephalomyelitis1 (2005) (153)
Non-TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug: A Randomized Clinical Trial. (2016) (152)
CD8+ T-Cell Responses Identify β-Cell Autoimmunity in Human Type 1 Diabetes (2007) (146)
Mature mainstream TCR alpha beta+CD4+ thymocytes expressing L-selectin mediate "active tolerance" in the nonobese diabetic mouse. (1998) (145)
Treatment with granulocyte colony-stimulating factor prevents diabetes in NOD mice by recruiting plasmacytoid dendritic cells and functional CD4(+)CD25(+) regulatory T-cells. (2005) (141)
Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. (1999) (139)
Jagged2-expressing hematopoietic progenitors promote regulatory T cell expansion in the periphery through notch signaling. (2006) (131)
Role of cytotoxic T cells in chronic alopecia areata. (2000) (126)
T cells and B cells in chronic renal failure. (1996) (125)
The hygiene hypothesis: an explanation for the increased frequency of insulin-dependent diabetes. (2012) (123)
Diversity of regulatory CD4+T cells controlling distinct organ-specific autoimmune diseases (2003) (118)
Unique role of CD4+CD62L+ regulatory T cells in the control of autoimmune diabetes in T cell receptor transgenic mice (2004) (113)
Prophylactic use of OKT3 monoclonal antibody in cadaver kidney recipients. Utilization of OKT3 as the sole immunosuppressive agent. (1986) (111)
Presence of preactivated T cells in hemodialyzed patients: their possible role in altered immunity. (1986) (109)
Short-Term Treatment With Anti-CD3 Antibody Reduces the Development and Progression of Atherosclerosis in Mice (2006) (109)
Humoral and Cellular Immune Responses after Influenza Vaccination in Kidney Transplant Recipients (2009) (108)
Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease. (2006) (107)
In vivo T cell preactivation in chronic uremic hemodialyzed and non-hemodialyzed patients. (1989) (106)
In vivo inhibition of NF-kappa B in T-lineage cells leads to a dramatic decrease in cell proliferation and cytokine production and to increased cell apoptosis in response to mitogenic stimuli, but not to abnormal thymopoiesis. (1999) (105)
Corticosteroid inhibition of the OKT3-induced cytokine-related syndrome--dosage and kinetics prerequisites. (1991) (102)
Immune therapy for type 1 diabetes mellitus—what is unique about anti-CD3 antibodies? (2010) (98)
Anemia after Late Introduction of Sirolimus May Correlate with Biochemical Evidence of a Chronic Inflammatory State (2005) (98)
Recent Lessons Learned From Prevention and Recent-Onset Type 1 Diabetes Immunotherapy Trials (2012) (97)
TGFβ-dependent expression of PD-1 and PD-L1 controls CD8+ T cell anergy in transplant tolerance (2015) (96)
Immune system dysregulation in uremia. (1994) (95)
Mutations in COPA lead to abnormal trafficking of STING to the Golgi and interferon signaling (2020) (94)
The human immune response to the OKT3 monoclonal antibody is oligoclonal. (1986) (94)
The Frequency and Immunodominance of Islet-Specific CD8+ T-cell Responses Change after Type 1 Diabetes Diagnosis and Treatment (2008) (93)
Poor Anti-SARS-CoV-2 Humoral and T-cell Responses After 2 Injections of mRNA Vaccine in Kidney Transplant Recipients Treated with Belatacept. (2021) (90)
Hepatitis B virus DNA in mononuclear blood cells. A frequent event in hepatitis B surface antigen-positive and -negative patients with acute and chronic liver disease. (1986) (88)
Randomized controlled trial comparing the effectiveness of 308‐nm excimer laser alone or in combination with topical hydrocortisone 17‐butyrate cream in the treatment of vitiligo of the face and neck (2008) (88)
Cross‐Validation of IFN‐γ Elispot Assay for Measuring Alloreactive Memory/Effector T Cell Responses in Renal Transplant Recipients (2013) (86)
Anti-CD3 clinical trials in type 1 diabetes mellitus. (2013) (85)
Anti-tumor necrosis factor modulates anti-CD3-triggered T cell cytokine gene expression in vivo. (1994) (82)
Antigenic modulation - a major mechanism of antibody action. (1984) (80)
Immune deficiency of the uremic patient. (1990) (80)
Transforming Growth Factor-β and Natural Killer T-Cells Are Involved in the Protective Effect of a Bacterial Extract on Type 1 Diabetes (2006) (78)
Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients. (2010) (77)
EVIDENCE THAT ANTIHUMAN TUMOR NECROSIS FACTOR MONOCLONAL ANTIBODY PREVENTS OKT3‐INDUCED ACUTE SYNDROME (1992) (74)
One-month prophylactic use of OKT3 in cadaver kidney transplant recipients. (1988) (74)
Immunological effects of high dose administration of anti-CD4 antibody in rheumatoid arthritis patients. (1991) (74)
Studies on T cell subsets and functions in leprosy. (1981) (72)
Treatment of recalcitrant plaque psoriasis with a humanized non-depleting antibody to CD4. (1998) (70)
Effects of cyclosporine in severe systemic lupus erythematosus. (1987) (66)
Transforming growth factor‐β and T‐cell‐mediated immunoregulation in the control of autoimmune diabetes (2006) (66)
Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide for Primary Immunodeficiencies and Inherited Disorders in Children. (2019) (65)
In vitro inhibition of pancreatic B cell function by lymphocytes from diabetics with associated autoimmune diseases: a T cell phenomenon. (1982) (64)
Reduction of morbidity and cytokine release in anti-CD3 MoAb-treated mice by corticosteroids. (1990) (62)
Abnormalities of T-cell subsets in glomerulonephritis and systemic lupus erythematosus. (1981) (61)
Nonmitogenic CD3 Antibody Reverses Virally Induced (Rat Insulin Promoter-Lymphocytic Choriomeningitis Virus) Autoimmune Diabetes Without Impeding Viral Clearance1 (2002) (60)
Role of GM-CSF in tolerance induction by mobilized hematopoietic progenitors. (2008) (58)
Immune therapies of autoimmune diseases: are we approaching a real cure? (2006) (57)
IMPLICATIONS OF DE NOVO ELAM‐1 AND VCAM‐1 EXPRESSION IN HUMAN CARDIAC ALLOGRAFT REJECTION (1993) (57)
Faculty Opinions recommendation of Extrathymic generation of regulatory T cells in placental mammals mitigates maternal-fetal conflict. (2013) (56)
A pilot trial of recombinant human interleukin-10 in kidney transplant recipients receiving OKT3 induction therapy. (1997) (55)
Consensus statement regarding OKT3-induced cytokine-release syndrome and human antimouse antibodies. (1993) (54)
Severe neonatal myasthenia due to maternal anti-MuSK antibodies (2008) (54)
Human CD3 Transgenic Mice: Preclinical Testing of Antibodies Promoting Immune Tolerance (2011) (53)
ZnT8 Is a Major CD8+ T Cell–Recognized Autoantigen in Pediatric Type 1 Diabetes (2012) (52)
Induction of Allograft Tolerance by Monoclonal CD3 Antibodies: A Matter of Timing (2012) (51)
Deficiency of immunoregulatory indoleamine 2,3-dioxygenase 1in juvenile diabetes. (2018) (51)
Cascade modulation by anti‐tumor necrosis factor monoclonal antibody of interferon‐γ, interleukin 3 and interleukin 6 release after triggering of the CD33/T cell receptor activation pathway (1991) (50)
Decreased Production of Interleukin‐2 in Schizophrenia (1987) (50)
12-Month Follow-up After Successful Infliximab Therapy in Pediatric Crohn Disease (2008) (49)
Regulatory T Cells in the Control of Autoimmune Diabetes: The Case of the NOD Mouse (2005) (49)
The OKT3 immunosuppressive effect. In situ antigenic modulation of human graft-infiltrating T cells. (1990) (49)
Quantitative assessment of antibodies to ribonucleoproteins in primary Sjögren syndrome: correlation with B-cell biomarkers and disease activity (2008) (49)
The anti-CD3-induced syndrome: a consequence of massive in vivo cell activation. (1991) (48)
Inducing and Administering Tregs to Treat Human Disease (2016) (47)
T cell subset modulation of immunoglobulin production in IgA nephropathy and membranous glomerulonephritis. (1984) (47)
Transforming growth factor-beta and natural killer T-cells are involved in the protective effect of a bacterial extract on type 1 diabetes. (2006) (45)
Toward cell-based therapy of type I diabetes. (2008) (45)
Long-Term Reversal of Established Autoimmunity upon Transient Blockade of the LFA-1/Intercellular Adhesion Molecule-1 Pathway1 (2002) (45)
Efficacy of JAK1/2 inhibition in the treatment of chilblain lupus due to TREX1 deficiency (2018) (44)
Outcome of Kidney Transplantations Performed With Preformed Donor‐Specific Antibodies of Unknown Etiology (2014) (43)
Key Role of the GITR/GITRLigand Pathway in the Development of Murine Autoimmune Diabetes: A Potential Therapeutic Target (2009) (42)
Immunoregulatory Pathways Controlling Progression of Autoimmunity in NOD Mice (2008) (41)
Delayed Anti-CD3 Therapy Results in Depletion of Alloreactive T Cells and the Dominance of Foxp3+CD4+ Graft Infiltrating Cells (2013) (41)
Inter‐mouse strain differences in the in vivo anti‐CD3 induced cytokine release (1991) (41)
CD3-specific antibodies restore self-tolerance: mechanisms and clinical applications. (2005) (40)
G-CSF treatment prevents cyclophosphamide acceleration of autoimmune diabetes in the NOD mouse. (2005) (40)
The Activity of Immunoregulatory T Cells Mediating Active Tolerance Is Potentiated in Nonobese Diabetic Mice by an IL-4-Based Retroviral Gene Therapy1 (2001) (39)
OKT3-induced cytokine-release syndrome: prevention effect of anti-tumor necrosis factor monoclonal antibody. (1993) (39)
A View on Beta Cell Transplantation in Diabetes (2002) (38)
Pharmacokinetics and Antibody Responses to the CD3 Antibody Otelixizumab Used in the Treatment of Type 1 Diabetes (2010) (38)
Immunological considerations of the uremic and dialyzed patient. (1994) (38)
In vivo blockade of the Fas-Fas ligand pathway inhibits cyclophosphamide-induced diabetes in NOD mice. (2001) (36)
Circulating IL-17-producing mucosal-associated invariant T cells (MAIT) are associated with symptoms in children with asthma. (2017) (36)
Restricted specificity of peripheral alloreactive memory B cells in HLA-sensitized patients awaiting a kidney transplant. (2015) (36)
Unusually restricted anti‐isotype human immune response to OKT3 monoclonal antibody (1984) (35)
PREDICTION OF SUCCESSFUL ALLOGRAFT REJECTION RETREATMENT WITH OKT31,2 (1992) (35)
CD3 antibody treatment stimulates the functional capability of regulatory T cells. (2003) (35)
A historical view from thirty eventful years of immunotherapy in autoimmune diabetes. (2011) (35)
The immune response against therapeutic monoclonal antibodies. (1986) (35)
Understanding Pathogenesis and Care Challenges of Immune Reconstitution Inflammatory Syndrome in Fungal Infections (2018) (34)
The impact of dietary therapy on clinical and biologic parameters of pediatric patients with eosinophilic esophagitis. (2014) (33)
Report from the 1st International NOD Mouse T-Cell Workshop and the follow-up mini-workshop. (2001) (33)
Combining Autologous Dendritic Cell Therapy with CD3 Antibodies Promotes Regulatory T Cells and Permanent Islet Allograft Acceptance (2014) (32)
Humoral immune response against OKT3. (1993) (32)
Adaptive human regulatory T cells: myth or reality? (2006) (31)
Efficacy of Rituximab in Refractory Generalized anti-AChR Myasthenia Gravis. (2018) (30)
Clinical immunologic interventions for the treatment of type 1 diabetes. (2012) (30)
Immunologic monitoring of Orthoclone OKT3-treated patients: the problem of antimonoclonal immune response. (1987) (29)
99th Dahlem Conference on Infection, Inflammation and Chronic Inflammatory Disorders: Immune therapies of type 1 diabetes: new opportunities based on the hygiene hypothesis (2010) (29)
The effects of donor and recipient endotoxemia on TNF alpha production and mortality in the rat model of syngenic orthotopic liver transplantation. (1995) (29)
OKT3 in organ transplantation (1991) (29)
Peripheral B-Cell Phenotype and BAFF Levels are Associated With HLA Immunization in Patients Awaiting Kidney Transplantation (2014) (29)
Anti-TNF abrogates the cytokine-related anti-CD3 induced syndrome. (1991) (29)
Triggering the TCR Developmental Checkpoint Activates a Therapeutically Targetable Tumor Suppressive Pathway in T-cell Leukemia. (2016) (28)
Restoration of self-tolerance is a feasible approach to control ongoing beta-cell specific autoreactivity: its relevance for treatment in established diabetes and islet transplantation (2001) (27)
Interest in and limitations of monoclonal anti-T-cell antibodies for the follow-up of renal transplant patients. (1983) (27)
Natural and induced T CD4+CD25+FOXP3+ regulatory T cells. (2011) (27)
IMMUNOLOGICAL CONSEQUENCES AND TRAFFICKING OF HUMAN REGULATORY MACROPHAGES ADMINISTERED TO RENAL TRANSPLANT RECIPIENTS (2011) (26)
FOXP3-enriched infiltrates associated with better outcome in renal allografts with inflamed fibrosis. (2009) (26)
Immunogenicity of BNT162b2 vaccine against the Alpha and Delta variants in immunocompromised patients with systemic inflammatory diseases (2022) (25)
Immunologic monitoring during OKT3 therapy. (1993) (25)
Concise Review: Pluripotent Stem Cell‐Derived Cardiac Cells, A Promising Cell Source for Therapy of Heart Failure: Where Do We Stand? (2016) (25)
Immune response to human embryonic stem cell-derived cardiac progenitors and adipose-derived stromal cells (2012) (25)
Chemical immunosuppression in islet transplantation--friend or foe? (2008) (25)
CD3 antibodies as unique tools to restore self-tolerance in established autoimmunity their mode of action and clinical application in type 1 diabetes. (2008) (25)
Anti-CD3 antibodies: towards clinical antigen-specific immunomodulation. (2004) (25)
The Proteasome Inhibitor Bortezomib Controls Indoleamine 2,3-Dioxygenase 1 Breakdown and Restores Immune Regulation in Autoimmune Diabetes (2017) (24)
Do NKT cells control autoimmunity? (2002) (24)
Mature Mainstream TCRαβ+CD4+ Thymocytes Expressing L-Selectin Mediate “Active Tolerance” in the Nonobese Diabetic Mouse (1998) (24)
Clinical Use of OKT3: The Role of Cytokine Release and Xenosensitization (1988) (24)
Early defect of immunoregulatory T cells in autoimmune diabetes. (1996) (23)
ONE‐MONTH PROPHYLACTIC USE OF OKT3 IN CADAVER KIDNEY TRANSPLANT RECIPIENTS (1988) (23)
The Induction and Maintenance of Transplant Tolerance Engages Both Regulatory and Anergic CD4+ T cells (2017) (23)
[Remission of established disease in diabetic NOD mice induced by anti-CD3 monoclonal antibody]. (1992) (23)
Proinsulin: a unique autoantigen triggering autoimmune diabetes. (2006) (22)
Intraocular TNF in endotoxin- and S-antigen-induced uveitis: in vitro synthesis of TNF by retinal Müller glial and pigment epithelial cells (1994) (22)
HILDA/LIF, G.CSF, IL‐1β, IL‐6, AND TNFα PRODUCTION DURING ACUTE REJECTION OF HUMAN KIDNEY ALLOGRAFTS (1993) (21)
Regulatory mechanisms of immune tolerance in type 1 diabetes and their failures. (2016) (21)
Safety and efficacy of therapeutic monoclonal antibodies in clinical therapy. (1993) (21)
Human peripheral blood DNAM-1neg NK cells are a terminally differentiated subset with limited effector functions. (2019) (21)
Autoimmune Diabetes: An Overview of Experimental Models and Novel Therapeutics. (2016) (21)
Severe human herpesvirus-8 primary infection in a renal transplant patient successfully treated with anti-CD20 monoclonal antibody. (2006) (21)
CD3-Specific Antibodies as Promising Tools to Aim at Immune Tolerance in the Clinic (2006) (20)
Casein‐specific IL‐4‐ and IL‐13‐secreting T cells: a tool to implement diagnosis of cow's milk allergy (2014) (20)
Autoimmune diabetes: how many steps for one disease? (1997) (20)
Therapeutic Use of a Selective S1P1 Receptor Modulator Ponesimod in Autoimmune Diabetes (2013) (19)
The IgE humoral response in OKT3-treated patients. Incidence and fine specificity. (1996) (19)
The effect of immunosuppressive agents on T-cell subsets, as evaluated by use of monoclonal anti-T-cell antibodies. (1981) (19)
Monitoring of Anti-transglutaminase Autoantibodies in Pediatric Celiac Disease Using a Sensitive Radiobinding Assay (2012) (19)
Quantification of circulating house dust mite‐specific IL‐4‐ and IL‐13‐secreting T cells correlates with rhinitis severity in asthmatic children and varies with the seasons (2014) (19)
Aberrant Function and Long-Term Survival of Mouse β Cells Exposed In Vitro to High Glucose Concentrations (1994) (19)
A randomized trial comparing the efficacy of OKT3 used to prevent or to treat rejection. (1989) (18)
The long and winding road towards induction of allograft tolerance in the clinic (2008) (18)
Infliximab paradoxical psoriasis in a cohort of children with inflammatory bowel disease. (2019) (18)
Characterization of histamine H1 binding sites on human T lymphocytes by means of 125I-iodobolpyramine. Preferential expression of H1 receptors on CD8 T lymphocytes. (1990) (18)
Latent hepatitis B virus (HBV) infection in systemic necrotizing vasculitis. (1991) (18)
Use of CD3 antibodies in transplantation and autoimmune diseases. (1994) (17)
Monoclonal antibody-based strategies in autoimmunity and transplantation. (2005) (17)
Absence of clinical symptoms following the first injection of anti-T cell receptor monoclonal antibody (BMA 031) despite isolated TNF release. (1993) (17)
Distribution of hepatitis B virus DNA sequences in different peripheral blood mononuclear cell subsets in HBs antigen‐positive and negative patients (1994) (16)
Long-term CD4 lymphopenia is associated with accelerated decline of kidney allograft function. (2016) (16)
Reactivity of histiocytosis X cells with monoclonal antibodies. (1983) (16)
Fine specificity of antibodies produced in rhesus monkeys following in vivo treatment with anti‐T cell murine monoclonal antibodies (1986) (16)
In vivo infusion of anti LFA-1 antibody in HLA non-identical bone marrow transplantation in children: serum concentrations and biological effects. (1989) (16)
In vivo anti-CD3-driven cell activation. Cellular source of induced tumor necrosis factor, interleukin-1 beta, and interleukin-6. (1996) (15)
Mucosal administration of CD3-specific monoclonal antibody inhibits diabetes in NOD mice and in a preclinical mouse model transgenic for the CD3 epsilon chain. (2017) (15)
Regulation of the β-cell inflammasome and contribution to stress-induced cellular dysfunction and apoptosis (2018) (15)
Suppression of the humoral response to anti-CD3 monoclonal antibody. (1989) (15)
Precision medicine for autoimmune disease (2016) (15)
IN-VIVO ANTI-CD3 TREATMENT OF AUTOIMMUNE PATIENTS (1989) (14)
CD3 monoclonal antibodies: a first step towards operational immune tolerance in the clinic. (2012) (14)
Monoclonal antibodies to CD3 as immunosuppressants. (1990) (13)
CD3 antibody-induced IL-10 in renal allograft recipients: an in vivo and in vitro analysis. (1999) (13)
Frequent lymphocytes infection by hepatitis B virus in haemophiliacs (1987) (13)
Sparing of first dose effect of monovalent anti-CD3 antibody used in allograft rejection is associated with diminished release of pro-inflammatory cytokines. (1994) (13)
Biotherapies targeting T and B cells: from immune suppression to immune tolerance. (2015) (13)
In vitro correlates of the acute toxic syndrome induced by some monoclonal antibodies: a rationale for the design of predictive tests. (1995) (13)
Anti-OKT3 response following prophylactic treatment in paediatric kidney transplant recipients (1993) (12)
Oral histone deacetylase inhibitor synergises with T cell targeted immunotherapy to preserve beta cell metabolic function and induce stable remission of new-onset autoimmune diabetes in NOD mice (2018) (12)
In vivo soluble tumor necrosis factor receptor release in OKT3-treated patients. Differential regulation of TNF-sR55 and TNF-sR75. (1995) (12)
Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma (2021) (12)
In vivo activation of transferred regulatory T cells specific for third‐party exogenous antigen controls GVH disease in mice (2013) (12)
Progress towards the clinical use of CD3 monoclonal antibodies in the treatment of autoimmunity (2009) (12)
Harnessing regulatory T cells for transplant tolerance in the clinic through mTOR inhibition: myth or reality? (2011) (11)
Trough Levels of Infliximab at W6 Are Predictive of Remission at W14 in Pediatric Crohn Disease. (2020) (11)
In vitro T cell unresponsiveness following low‐dose injection of anti‐CD3 MoAb (1996) (11)
The Effects of Ciclosporin in Twelve Patients with Severe Systemic Lupus (1985) (11)
Markers of microbial exposure lower the incidence of atopic dermatitis (2019) (11)
In vivo cyclosporine A treatment inhibits spleen cell mitogen-triggered free [Ca2+] increase. (1988) (10)
Immunological follow-up of renal allograft recipients treated with the BMA 031 (anti-TCR) monoclonal antibody. (1990) (10)
In vivo T lymphocyte activation induced in mice following the injection of anti-CD3 monoclonal antibody. (1990) (10)
Monoclonal antibodies in transplantation (1995) (10)
Correction: Antibiotics in Early Life Alter the Gut Microbiome and Increase Disease Incidence in a Spontaneous Mouse Model of Autoimmune Insulin-Dependent Diabetes (2016) (10)
Control of asthma by omalizumab: the role of CD4+Foxp3+ regulatory T cells (2016) (10)
New generation CD3 monoclonal antibodies: are we ready to have them back in clinical transplantation? (2010) (9)
In vivo use of OKT3: main issues for the monitoring of treated patients. (1990) (9)
Human interleukin DA-1a (HILDA)/LIF,G-CSF, IL-1 beta, IL-6, and TNF alpha production during acute kidney graft rejection episodes. (1993) (9)
Intragraft mechanisms associated with the immunosuppressive versus the tolerogenic effect of CD3 antibodies in a mouse model of islet allografts. (2013) (9)
Biological immunosuppressants: the way to clinical transplantation tolerance. (1997) (9)
Remission of chronic acne fulminans and severe hidradenitis suppurativa with targeted antibiotherapy (2019) (9)
Teaching the immune system “self” respect and tolerance (2014) (9)
[Acute clinical syndrome associated with OKT3 administration. Prevention by single injection of an anti-human TNF monoclonal antibody]. (1991) (9)
A future for CD3 antibodies in immunotherapy of type 1 diabetes (2019) (9)
The effects of immunomodulation on peripheral T cell subsets. (1982) (8)
Chronic Disseminated Candidiasis During Hematological Maligancies: An Immune Reconstitution Inflammatory Syndrome with Expansion of Pathogen-Specific TH1 T Cells. (2019) (8)
Immunogenicity of BNT162b2 vaccine Against the Alpha and Delta Variants in Immunocompromised Patients (2021) (8)
Therapeutic monoclonal antibodies in transplantation. (1993) (8)
Regulatory T cell-subset imbalance in chronic active hepatitis (1982) (8)
Effect of Cyclosporin on Interleukin 2–Related T-Lymphocyte Parameters in IDDM Patients (1989) (8)
Selective immunosuppression with anti-T cell monoclonal antibodies. (1992) (8)
[Dysregulation of the immune system in chronic uremic and hemodialysed patients]. (1995) (8)
In vitro and in vivo action of cyclosporin A on the induction of human interleukin-2 receptor alpha and beta chains. (1989) (8)
Immunological and virological profile of children with chilblain‐like lesions and SARS‐CoV‐2 (2020) (8)
The significance of T-cell subsets defined by monoclonal antibodies in human diseases. (1982) (8)
Resetting the functional capacity of regulatory T cells: a novel immunotherapeutic strategy to promote immune tolerance (2005) (8)
[Increase of CXCL10 serum level in systemic sclerosis interstitial pneumonia]. (2009) (8)
Pancreas and islet transplantation in man. (1992) (7)
In vivo T cell activation properties of anti-T cell monoclonal antibodies. (1993) (7)
Fine-needle aspiration biopsy of human liver allografts. Correlation with liver histology for the diagnosis of acute rejection. (1990) (7)
Genetic control of hepatitis A severity and susceptibility to allergy. (2011) (7)
Control of Immune Response to Allogeneic Embryonic Stem Cells by CD3 Antibody–Mediated Operational Tolerance Induction (2016) (7)
A selective CD28 antagonist and rapamycin synergise to protect against spontaneous autoimmune diabetes in NOD mice (2018) (7)
Revisiting autoimmune gastritis in children and adolescents with type 1 diabetes (2017) (7)
Diabetes: Type 1 diabetes mellitus—a door opening to a real therapy? (2011) (7)
Differential Impact of T-bet and IFN&ggr; on Pancreatic Islet Allograft Rejection (2018) (6)
The use of monoclonal antibodies to restore self-tolerance in established autoimmunity. (2002) (6)
Unique role of CD 4 CD 62 L regulatory T cells in the control of autoimmune diabetes in T cell receptor transgenic mice (2004) (6)
Tolerogenic antibodies and fusion proteins to prevent graft rejection and treat autoimmunity. (1998) (6)
Anti-CD3 antibodies. (1993) (6)
Allograft rejection: the role of the cytokine network. (1992) (6)
Aberrant Distribution of CD4 and CD8 Lymphocyte Subsets in Recent-Onset IDDM Patients: Effect of Cyclosporin (1993) (6)
Devising murine models to better adapt clinical protocols: sequential low-dose treatment with anti-CD3 and anti-CD4 monoclonal antibodies to prevent fully mismatched allograft rejection. (1993) (6)
Clinical significance of T cell monitoring during antithymocyte globulin induction in renal transplantation. (1997) (6)
First and second course of OKT3 monoclonal anti-T cell antibody for treatment of renal allograft rejection followed by testing for anti-OKT3 IgM and/or IgG immunization. (1990) (6)
Therapeutic use of monoclonal antibodies in kidney transplantation. (1985) (5)
Protection from autoimmunity: Immunological indifference versus T‐cell mediated suppression? (2006) (5)
World Diabetes Day: Perspectives on immunotherapy of Type 1 Diabetes (2015) (5)
[Thyroiditis and gluten intolerance: extrapancreatic auto-immune diseases associated with type 1 diabetes]. (2007) (5)
Dissociation of humoral and cellular immune responses in kidney transplant recipients with EBV mucocutaneous ulcer (2020) (5)
NONSTEROID ANTIINFLAMMATORY AGENTS AS A SUBSTITUTE TREATMENT FOR STEROIDS IN ATGAMTREATED CADAVER KIDNEY RECIPIENTS (1984) (5)
Autoantibodies in recent onset type‐1 diabetic patients to a Mr 60K microsomal hepatic protein: new evidence for autoantibodies to the type‐2 glucose transporter (2000) (5)
Deficiency of suppressor/cytotoxic T-cells in idiopathic membranous glomerulonephritis (1980) (5)
HILDA/LIF, G.CSF, IL-1 beta, IL-6, and TNF alpha production during acute rejection of human kidney allografts. (1993) (5)
The use of CD3-specific antibodies in autoimmune diabetes: a step toward the induction of immune tolerance in the clinic. (2008) (5)
The therapeutic use of monoclonal antibodies. (1988) (5)
T cell subpopulations defined by monoclonal antibodies in autoimmune hemolytic anemia. (1983) (5)
Variability of Primary Sjögren's Syndrome Is Driven by Interferon‐α and Interferon‐α Blood Levels Are Associated With the Class II HLA–DQ Locus (2022) (4)
Clinical applications of anti-T-cell monoclonal antibodies. (1991) (4)
Immunomodulation of T cells by thymic hormone and monoclonal anti-T cell antibody. (1982) (4)
Immunosuppression in insulin-dependent diabetes mellitus: from cellular selectivity towards autoantigen specificity. (1995) (4)
Questioning four preconceived ideas on immunotherapy of clinical type 1 diabetes: lessons from recent CD3 antibody trials. (2005) (4)
3-months elimination diet in childhood EoE: nutritional and immunological aspects (2013) (4)
Therapeutic use of the OKT3 anti-T cell monoclonal antibody: mode of action and side effects. (1988) (4)
Polyclonal and monoclonal antibodies directed against SK & F 94461, a specific H1 histamine receptor ligand. (1988) (4)
Therapeutic Targeting of B Cells and T Cells in Autoimmune Diabetes (2013) (4)
Therapeutic Immunosuppression (2001) (3)
Treatment of Autoimmune Disease: Biological and Molecular Therapies (2014) (3)
Anti-CD38 therapy impairs SARS-CoV-2 vaccine response in multiple myeloma patients (2021) (3)
Immunotherapy of type 1 diabetes mellitus. (2001) (3)
Emerging Therapies for Autoimmune Diseases (2006) (3)
[Preventive treatment of rejection by the prolonged administration of OKT3: decrease of the immune response of the host]. (1987) (3)
[T lymphocyte activation induced by monoclonal anti-CD3 antibodies: physiopathology of cytokine release]. (1991) (3)
The Concerted Action of Multiple Mechanisms to Induce and Sustain Transplant Tolerance (2018) (3)
Role of interleukin-2 receptors in the suppressive effect of spleen cells from anti-CD3-treated mice. (1995) (3)
Chronic Disseminated Candidiasis During Hematological Malignancies: An Immune Reconstitution Inflammatory Syndrome With Expansion of Pathogen-Specific T Helper Type 1 Cells (2020) (3)
Revisiting the phenotypic and genetic profiling of anergic T cells mediating long-term transplant tolerance (2017) (3)
Suppression of the humoral response to anti-CD3 mAB by pretreatment with anti-CD4 mAB. (1989) (3)
Tolerance induction in the adult: 'danger' at Le Bischenberg. (1995) (3)
The effects of interleukin-1 on pancreatic beta cell function in vitro depend on the glucose concentration. (1992) (3)
[T CD57+ lymphocytes in kidney transplanted patients. Phenotypic and functional study]. (1992) (3)
Activation lymphocytaire T induite in vivo par la première injection de l'anticorps monoclonal OKT3 (1988) (2)
COVID-19: individual and herd immunity. (2021) (2)
In situ antigenic modulation of human graft-infiltrating T cells is induced by OKT3 treatment. (1990) (2)
The clinical use of monoclonal anti-t-cell antibodies (1984) (2)
IL-4 and IL-17 Are Required for House Dust Mite-Driven Airway Hyperresponsiveness in Autoimmune Diabetes-Prone Non-Obese Diabetic Mice (2021) (2)
Organ transplantation and autoimmunity: common mechanisms common therapies. (2011) (2)
Anti-T-Cell Monoclonal Antibodies as Immunosuppressive Agents (1992) (2)
Characterization of T cells cultured from fine needle aspirates of human renal allografts during rejection. (1985) (2)
The induction and Maintenance of Transplant Tolerance engages Both regulatory and anergic cD 4 + T cells (2019) (2)
De novo germline mutation in the dual specificity phosphatase 10 gene accelerates autoimmune diabetes (2021) (2)
Animal Models of Type 1 Diabetes Mellitus (2007) (2)
[Inflammation and rejection]. (1990) (2)
EVIDENCE THAT TREATMENT WITH DHRS9+ REGULATORY MACROPHAGES INDUCED BY FCγRIII LIGATION AND IFN-γ STIMULATION PROMOTES RENAL ALLOGRAFT TOLERANCE IN PATIENTS: 3261 (2010) (2)
DIABETIC STUDIES The Review of Chapter IV . 2 CD 3 Monoclonal Antibodies : A First Step Towards Operational Immune Tolerance in the Clinic (2013) (2)
Chapter 2 CD3 Antibodies as Unique Tools to Restore Self-Tolerance in Established Autoimmunity (2008) (2)
SCREENING FOR CELIAC DISEASE IN A FRENCH ADULT POPULATION: LOWER THAN EXPECTED PREVALENCE: PG1-20 (2005) (1)
Donor-specific T cell lines grown from fine-needle aspirates of human renal allografts during acute rejection. (1987) (1)
Abstract 10471: Both Adipose-Derived Stroma Cells and Coronary Artery Disease Positively Modulate the Immune Response to Human Embryonic Stem Cell-Derived Cardiac Progenitors (2010) (1)
Functional analysis of lymphocytes recovered from human allograft undergoing rejection. (1987) (1)
Modulation of autoimmune diabetes by N-ethyl-N-nitrosourea- induced mutations in non-obese diabetic mice (2022) (1)
P0080 PP CLINICAL OUTCOME OF IPEX SYNDROME: SURVEY OF 11 CONSECUTIVE BOYS (2004) (1)
From the 1 st International NOD Mouse T-Cell Workshop and the Follow-Up Mini-Workshop (2001) (1)
Monoclonal antibodies. (1989) (1)
Clinical aspects of immunologic monitoring. (1999) (1)
T-cell receptor-based immunointervention in autoimmune diseases. Therapeutic use of monoclonal antibodies. (1993) (1)
Adalimumab Therapy in Pediatric Crohn Disease: A 2-Year Follow-Up Comparing “Top-Down” and “Step-Up” Strategies (2022) (1)
Weaned from the needle (2006) (1)
Effective Anti–SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell Disorders (2022) (1)
[Immunotolerance and autoimmunity]. (2000) (1)
G.P.3 09 Severe neonatal myasthenia due to maternal anti-MuSK antibodies (2006) (1)
Absence of severe COVID-19 in patients with clonal mast cells activation disorders: effective anti-SARS-CoV-2 immune response (2021) (1)
[Anti-CD3 monoclonal antibodies: a new step towards therapy in new-onset type 1 diabetes]. (2006) (1)
Interleukin-2 production and targeting in hemodialyzed patients. (1987) (1)
[One step towards restoration of self-tolerance in human autoimmune diseases]. (2007) (1)
Monoclonal antibodies as therapeutic tools in medicine (1985) (1)
[Role of interleukins in autoimmunity]. (1984) (1)
Analyzing Casein-Specific IL-4 and IL-13 Secreting T-Cells: A Reliable Tool For Diagnosis Of Cow's Milk Allergy (2014) (0)
FUTURE GOALS FOR THERAPEUTIC MONOCLONAL ANTIBODIES (1995) (0)
The effect of cyclosporine A on humoral and cellular immunity in insulin-dependent (type I) diabetes mellitus. (1988) (0)
Editorial Board: Eur. J. Immunol. 1'17 (2017) (0)
Abstract 10901: CD3 Antibodies are a Promising Tool for Modulating the Immune Response to Embryonic Stem Cells and Their Cardiac Derivatives (2013) (0)
[T lymphocyte activation induced in vivo by the first injection of OKT3 monoclonal antibodies]. (1988) (0)
De novo germline mutation in the Dual Specificity Phosphatase 10 gene accelerates autoimmune diabetes in Non-Obese Diabetic (NOD) mice (2021) (0)
useful combination drug for transfection and in vivo expression of exogenous (1995) (0)
Tolerance Induction Versus Immunosuppression in Organ Transplant by CD3 Antibodies: A Matter of Timing: 2453 (2012) (0)
and Detection of Distinct Disease Subtypes Humoral Autoimmunity in Type 1 Diabetes: Prediction, Significance, (2012) (0)
Encephalomyelitis Established Experimental Autoimmune Unresponsiveness and Functional Reversal of T Cell + Monoclonal Antibody Induces CD 4 Treatment with Nonmitogenic Anti-CD 3 (2005) (0)
Autoimmune disorders: toward more efficient and safer therapies (2009) (0)
Regulatory T cells in type 1 autoimmune diabetes (2005) (0)
Faculty Opinions recommendation of Thymic development of autoreactive T cells in NOD mice is regulated in an age-dependent manner. (2014) (0)
The Immunological Basis of the Treatment of Glomerulonephritis (1981) (0)
Immunoregulatory Abnormalities in Primary Human Glomerulonephritis (1986) (0)
Antibody Therapeutics: Application to Autoimmunity (2019) (0)
Thymopoiesis Mitogenic Stimuli , But Not to Abnormal Increased Cell Apoptosis in Response to Proliferation and Cytokine Production and to Cells Leads to a Dramatic Decrease in Cell B in T-Lineage κ In Vivo Inhibition of NF - (1999) (0)
List of Contributors (2020) (0)
Autoantibody Monitoring After Pancreas Transplantation.: Abstract# 2175 (2014) (0)
synergize with ATDCs to promote CD 4 + Foxp 3 + Tregs and to switch the balance from rejection toward long-term acceptance of fully mismatched grafts . Materials and Methods Mice (2014) (0)
Dissociation of TNF and IL-1β production in chronic alcoholics without cirritosis (1991) (0)
Editorial Board: Eur. J. Immunol. 10'16 (2016) (0)
Allograft Acceptance Regulatory T Cells and Permanent Islet Therapy with CD3 Antibodies Promotes Combining Autologous Dendritic Cell (2014) (0)
[In vivo induction of antigenic modulation in man by an anti-T cell monoclonal antibody (author's transl)]. (1982) (0)
Diabetes Without Impeding Viral Clearance Choriomeningitis Virus) Autoimmune Induced (Rat Insulin Promoter-Lymphocytic Nonmitogenic CD3 Antibody Reverses Virally (2001) (0)
L-Selectin Mediate "Active Tolerance" in the Nonobese Diabetic Mouse 1 (1998) (0)
[Metabolic and immunologic effects of cyclosporine administration in new insulin-dependent diabetics]. (1985) (0)
Pathway the LFA-1 / Intercellular Adhesion Molecule-1 Autoimmunity upon Transient Blockade of Long-Term Reversal of Established Chatenoud and (2002) (0)
THU0248 Therapeutic Interest of anti-CD3 and Anti-Baff Monoclonal Antibodies in The Nod Model of Sjögren's Syndrome (2016) (0)
ANTI-INFLIXIMAB IMMUNIZATION AND CLINICAL OUTCOME IN PEDIATRIC REFRACTORY CROHN'S DISEASE: PG2-15 (2005) (0)
Chantal Kuhn Promoting Immune Tolerance Human CD 3 Transgenic Mice : Preclinical Testing of Antibodies (2011) (0)
Molecular Basis for Induction of Tolerance in Type I Diabetes (2007) (0)
Effect of anti-CD3 injection on hematopoiesis and IL-3-induced histamine and IL-6 production by progenitors (1994) (0)
Emerging therapeutic approaches to preserve beta cell function in type 1 DM (2008) (0)
DONOR-SPECIFIC IFN-GAMMA ELISPOT ASSAY AS A TOOL FOR TAILORING IMMUNOSUPPRESSION IN RENAL TRANSPLANTED PATIENTS (2006) (0)
Antibodies in the control of type I diabetes (2007) (0)
Retroviral Gene Therapy Nonobese Diabetic Mice by an IL-4-Based Mediating Active Tolerance Is Potentiated in The Activity of Immunoregulatory T Cells (2001) (0)
Sera from type I diabetes patients promote abnormal stimulation of B cell insulin release (1990) (0)
DB120562 9..17 (2012) (0)
[Monoclonal antibodies. Diagnostic and therapeutic use and prospects for the future]. (1993) (0)
[In vivo use of OKT3 monoclonal antibodies in recipients of renal allografts]. (1987) (0)
Prevention of diabetes recurrence after syngeneic islet transplantation in NOD mice by a combination of a vitamin D analog, TX527, anti-CD3 and cyclosporine A (2010) (0)
Free Communications (2012) (0)
HUMAN PERIPHERAL BLOOD DNAM-1NEG NK CELLS ARE A TERMINALLY DIFFERENTIATED SUBSET WITH IMMUNOREGULATORY PROPERTIES (2019) (0)
Editorial Board: Eur. J. Immunol. 12'16 (2016) (0)
Faculty Opinions recommendation of 2B4 (CD244) induced by selective CD28 blockade functionally regulates allograft-specific CD8+ T cell responses. (2014) (0)
Long lasting CD4 + T lymphopenia in kidney transplantation (2014) (0)
Hepatitis B virus (HBV) DNA in mononuclear blood cells of HBV carriers: analysis of patients with and without AIDS [abstract] (1986) (0)
Transplant Recipients Macrophages Administered to Renal and Trafficking of Human Regulatory Cutting Edge: Immunological Consequences (2011) (0)
[Present and future value of monoclonal antibodies in nephrology]. (1985) (0)
Characterization of T Cells Cultured From Fine Needle Aspirates of Human Renal Allografts During Rejection (1985) (0)
Immunologic problems and perspectives in the therapeutic use of monoclonal antibodies in nephrology. (1985) (0)
P4.49 Preventive therapy of severe neonatal myasthenia gravis during pregnancy (2011) (0)
TRANSPLANTATION BASIC SCIENCE, ALLOGENIC AND XENOGENIC TOLERANCE (2014) (0)
Prevention of diabetes recurrence after syngeneic transplantation in non-obese diabetic (NOD) mice by a combination of a vitamin D analog, TX527, anti-CD3 and cyclosporine A (2011) (0)
Rapid and Safe T Cell Immune Reconstitution By T Cell Progenitor Injection Following Haploidentical Transplantation for Severe Combined Immunodeficiency (SCID) (2021) (0)
The Need for Immune Modulation Despite Regenerative Medicine (2014) (0)
Redirecting the treatment and monitoring of organ transplant patients. (2010) (0)
Tolerance induction by monoclonal CD3 antibodies is dependent on indoleamine 2,3 dioxygenase (IDO) (56.5) (2012) (0)
Emerging Biological and Molecular Therapies in Autoimmune Disease (2020) (0)
Editorial Board: Eur. J. Immunol. 10'15 (2015) (0)
phase 2 study lymphoproliferative disorders: results of a prospective multicenter Efficacy and safety of rituximab in B-cell post-transplantation (2011) (0)
[Therapeutic use of monoclonal antilymphocyte antibodies]. (1983) (0)
CONTRIBUTION OF MONOCLONAL ANTI-T CELL ANTIBODY IN THE FOLLOW-UP AND THE IMMUNOSUPPRESSIVE TREATMENT OF RENAL TRANSPLANT PATIENTS (1984) (0)
Clinical Pharmacology of 0KT3 (1988) (0)
Response to the Comment by D. Bresson and M. von Herrath (2005) (0)
Antigen-Specific IL-13 Secretion in Children with Eosinophilic Esophagitis (2013) (0)
Unique features of human and monkey xenosensitization against anti-T cell murine monoclonals (1985) (0)
[Diagnostic and therapeutic use of monoclonal anti-T lymphocyte antibodies]. (1988) (0)
Utilisation clinique des anticorps anti-lymphocytes T (1990) (0)
Techniques for Characterization of Leucocyte Antigens and Utilization of Antibodies in Therapy (1984) (0)
Targeting activated T cells in type I diabetes and islet transplantation (2011) (0)
OR.71. Combination Therapy of Short-term Low-dose Anti-CD3 and Oral Administration of Genetically-modified Lactococcus Lactis Secreting Insulin and IL-10 Enhances Remission in New-onset Diabetic NOD Mice (2009) (0)
patient successfully treated with anti-CD20 monoclonal antibody Severe human herpesvirus-8 primary infection in a renal transplant (2012) (0)
Treg therapy and plasticity (SY6-3) Chairpersons: Shohei Hori, Maria-Grazia Roncarolo (2010) (0)
Monoclonal Antibody Targeting of the T Cell Receptor Complex (2001) (0)
Therapeutic anti-T-cell monoclonal antibodies (2001) (0)
The Therapeutic Use of Anti-CD3 Monoclonal Antibodies in Autoimmune Diseases-Application to Type I Insulin-Dependent Diabetes (1994) (0)
EFFICACY AND SAFETY OF RITUXIMAB IN B-CELL POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS: RESULTS OF A PROSPECTIVE MULTICENTRE PHASE II STUDY Running head: Rituximab in PTLD (2017) (0)
Established Experimental Autoimmune Unresponsiveness and Functional Reversal of Monoclonal Antibody Induces CD4+ T Cell Treatment with Nonmitogenic Anti-CD3 (2013) (0)
Pre-Transplant HLA Immunization in Kidney Transplant Recipients Is Characterized by an Activated Peripheral B Cell Phenotype and High Serum Levels of BAFF (2013) (0)
Polyclonal and Monoclonal Antibodies (2001) (0)
The Genetic Association of Variants in CD6, TNFRSF1A and IRF8 to Multiple Sclerosis: A Multicenter Case-Control Study (2011) (0)

This paper list is powered by the following services:

Lucienne Chatenoud's Academic­Influence.com Rankings

Why Is Lucienne Chatenoud Influential?

Lucienne Chatenoud's Published Works

Published Works

Lucienne Chatenoud's AcademicInfluence.com Rankings